BioSpace News Archive

Fresenius Kabi Receives U.S. Food and Drug Administration 510(k) Clearance for Wireless Agilia ® Connect Infusion System with Vigilant ® Software Suite-Vigilant ® Master Med Technology.

Can-Fite BioPharma Ltd today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (PTO) for its invention titled “Method for Treating Fibrotic Liver Tissue Using CL-IB MECA”.

Crinetics Pharmaceuticals, Inc. today announced the appointment of Caren Deardorf to the company’s board of directors.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2021.

Dante Labs today announced the launch of Dante Genomics, an online marketplace portal specifically dedicated to healthcare providers, clinics, researchers and governments which will offer advanced genomic services for research and clinical applications.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study.

Titan Medical Inc. today announced that the company plans to issue its year end 2021 financial results prior to market opening on Thursday, March 24, 2022. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights.

Arch Therapeutics, Inc. today announced it has entered into a distribution agreement with Centurion Therapeutics Inc. to expand sales opportunities for AC5 ® Advanced Wound System.

Seer, Inc. announced the publication of a study demonstrating the performance of the technology platform underlying the Proteograph Product Suite™ for deep, unbiased, precise, scalable proteomics.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced data demonstrating that Reachable Workspace (RWS) is a quantitative and relevant measurement of function that can be used to assess disease progression as well as response to treatment in people with facioscapulohumeral muscular dystrophy (FSHD).